Yale Testing Late-Stage COVID-19 Vaccine Candidate

The Yale School of Medicine and Yale-New Haven Hospital announced on August 17, 2020, the start of Phase 3 study of the BioNTech SE - Pfizer BNT162 vaccine candidate at the hospital. 'Using modified RNA is a novel way to create a vaccine for humans. Rather than using the part or whole of the actual virus in an inactive form to create immunity, this vaccine candidate uses a genetic code (modified RNA) to make the body generate proteins that resemble the SARS CoV-2 virus spike protein, thereby causing the development of antibodies against it.'